Zhejiang Hisun Pharmaceutical Dividends and Buybacks
Dividend criteria checks 0/6
Zhejiang Hisun Pharmaceutical does not currently pay a dividend.
Key information
0%
Dividend yield
1.1%
Buyback Yield
| Total Shareholder Yield | 1.1% |
| Future Dividend Yield | 0.7% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.170 |
| Payout ratio | 0% |
Recent dividend and buyback updates
Recent updates
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business
Sep 26
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
Apr 30Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel
Mar 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if 600267's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 600267's dividend payments have been increasing.
Dividend Yield vs Market
| Zhejiang Hisun Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (600267) | 0% |
| Market Bottom 25% (CN) | 0.6% |
| Market Top 25% (CN) | 2.1% |
| Industry Average (Pharmaceuticals) | 1.8% |
| Analyst forecast (600267) (up to 3 years) | 0.7% |
Notable Dividend: Unable to evaluate 600267's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 600267's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: 600267 is not paying a notable dividend for the CN market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 600267 has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 13:49 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Hisun Pharmaceutical Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Qiang | China International Capital Corporation Limited |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |